Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 104,139 | 139,259 | 122,449 | 88,543 | 80,026 |
| Marketable Securities | 635,062 | 643,860 | 605,231 | 730,766 | 843,503 |
| Receivables | 1,778 | 2,206 | 5,592 | 4,302 | 5,905 |
| Inventories | 11,374 | 8,492 | 5,176 | 4,060 | 2,485 |
| TOTAL | $791,656 | $832,772 | $784,935 | $870,007 | $975,145 |
| Non-Current Assets | |||||
| PPE Net | 21,438 | 22,987 | 25,438 | 27,382 | 29,195 |
| Investments And Advances | 271,727 | 313,874 | 298,352 | 280,845 | 255,836 |
| Other Non-Current Assets | 66,477 | 69,085 | 71,595 | 74,233 | 75,683 |
| TOTAL | $359,642 | $405,946 | $395,385 | $382,460 | $360,714 |
| Total Assets | $1,151,298 | $1,238,718 | $1,180,320 | $1,252,467 | $1,335,859 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,662 | 18,616 | 10,415 | 7,790 | 11,551 |
| Accrued Expenses | 22,459 | 30,350 | 29,756 | 28,383 | 19,747 |
| TOTAL | $45,113 | $62,629 | $53,596 | $48,396 | $45,792 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | N/A | 2,500 |
| Other Non-Current Liabilities | 69,659 | 75,275 | 76,554 | 80,001 | 82,338 |
| TOTAL | $69,659 | $75,275 | $76,554 | $80,001 | $82,614 |
| Total Liabilities | $114,772 | $137,904 | $130,150 | $128,397 | $128,406 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 55,581 | 55,285 | 54,945 | 54,818 | 54,789 |
| Common Shares | 72 | 71 | 71 | 71 | 71 |
| Retained earnings | -551,579 | -470,561 | -507,087 | -425,340 | -333,534 |
| Other shareholders' equity | -8,897 | -13,021 | -15,569 | -10,988 | -8,231 |
| TOTAL | $1,036,526 | $1,100,814 | $1,050,170 | $1,124,070 | $1,207,453 |
| Total Liabilities And Equity | $1,151,298 | $1,238,718 | $1,180,320 | $1,252,467 | $1,335,859 |